Evaluation of the Safety and Performance of Magneto PE Kit

Who can take part

• Clinical signs, symptoms and presentation consistent with acute PE
• PE symptom duration ≤ 14 days
• CTA evidence of PE
• RV/LV ratio ≥ 0.9
• Heart rate <130 BPM prior to procedure
• Subject medically eligible for interventional procedure
• Age ≥ 18 and <75 years
• Consent process is completed

Who cannot take part

• Cardiovascular or pulmonary surgery within last 7 days
• Anaphylactic reaction to radiographic contrast agents that cannot be pre-treated
• Current participation in another investigational drug or device treatment study
• Known bleeding diathesis or coagulation disorder
• Decompensated heart failure
• History of severe chronic pulmonary arterial hypertension
• History of underlying lung disease with oxygen dependence
• History of chest irradiation
• History of Heparin Induced Thrombocytopenia (HIT)
• Platelets < 100,000/µL
• Serum creatinine > 1.8 mg/dL
• INR>2
• Known left ventricular ejection fraction ≤ 30%
• Thrombolytic use within 14 days
• Any contraindication to systemic therapeutic doses of heparin or other anticoagulants
• Hemodynamic collapse at presentation
• Presence of Extra-Corporeal Membrane Oxygenation
• Major trauma ISS> 15 within 14 days
• FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
• Hematocrit < 28%
• Left bundle branch block
• PAP > 70 mmHg m
• Imaging evidence suggests subject is not appropriate for mechanical thrombectomy
• Presence of intracardiac lead in right ventricle or atrium
• Pacemaker or Implantable Cardioverter Defibrillator
• Presence of intracardiac thrombus
• Known right- to-left shunt,
• Female who is pregnant or nursing
• Life expectancy of < 90 days as determined by the investigator
• Subjects who are intubated